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Introduction: People with inherited and long- term conditions such as haemophilia 
have been shown to adapt to their levels of disability, often reporting better quality of 
life (QoL) than expected from the general population (the disability paradox).
Aim: To investigate the disability paradox in people with haemophilia in the United 
States by examining preference differences in health state valuations versus the gen-
eral population.
Methods: We conducted a discrete choice experiment including duration to capture 
valuations of health states based on patient- reported preferences. Participants in-
dicated their preferences for hypothetical health states using the EQ- 5D- 5L, where 
each participant completed 15 of the 120 choice tasks. Response inconsistencies were 
evaluated with dominated and repeated scenarios. Conditional- logit regressions with 
random sampling of the general population responses were used to match the sample 
of patients with haemophilia. We compared model estimates and derived preferences 
associated with EQ- 5D- 5L health states.
Results: After removing respondents with response inconsistencies, 1327/2138 
(62%) participants remained (177/283 haemophilia; 1150/1900 general population). 
Patients with haemophilia indicated higher preference value for 99% of EQ- 5D- 5L 
health states compared to the general population (when matched on age and gender). 
The mean health state valuation difference of 0.17 indicated a meaningful difference 
compared to a minimal clinically important difference threshold of 0.07. Results were 
consistent by haemophilia type and severity.
Conclusion: Our findings indicated the presence of a disability paradox among patients with 
haemophilia, who reported higher health states than the general population, suggesting the 
impact of haemophilia may be underestimated if general population value sets are used.
K E Y W O R D S
cost- effectiveness, haemophilia, health equity, patient- reported outcome measurement, 
quality of life
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1  |  BACKGROUND
Haemophilia is a lifelong genetic disorder associated with signifi-
cant clinical burden driven by haemarthrosis, joint damage and 
pain, with subsequent negative impact on patients’ mental health, 
daily functioning and overall quality of life (QoL).1,2 The substantial 
reductions in morbidity and mortality afforded by modern thera-
peutic advances have elevated the aims of haemophilia treatment 
to realize a functional cure and to bring health equity to patients 
with this persistent, lifelong condition.3 As such, the landmark im-
provements in clinical effectiveness have increased the importance 
of patient- centric outcomes related to well- being, functionality, and 
QoL.4- 7 Measuring the patient- reported impact of conditions with 
lasting disabilities, such as haemophilia, may include a counterintui-
tive phenomenon known as the ‘disability paradox’, where patients 
report good or excellent QoL while observers characterize the 
patients’ daily struggles much less favourably.8 This disease state 
adaptation is believed to derive from a re- prioritization of values, 
a recalibration of essential needs and/or a re- conceptualization of 
central beliefs as patients adapt to the effects of their condition.8,9 
Importantly, this can cause an underestimation of disease burden 
and an under- valuation of treatment effects in patient- reported 
outcomes research.
The QoL of an individual can be derived from preference- based 
measures of health such as the EuroQoL 5- Dimensions (EQ- 5D).10 
The EQ- 5D includes five domains: mobility, self- care, usual activities, 
pain/discomfort and anxiety/depression. Once the questionnaire is 
completed, a health state valuation (HSVs) can be generated using a 
scoring algorithm designed to be a cardinal index of utility anchored 
on full health (1) and death (0). Values generated provide a ‘utility 
value set’ for each state described by the classification system.11
Discrete choice experiments (DCE) are widely used to estimate 
HSVs. DCEs are an ordinal choice- based method, which assume that 
people generally choose the option that provides them with the 
highest level of utility.12 In DCEs, respondents are typically asked 
to choose between choice tasks consisting of health scenarios. Each 
scenario consists of attributes and severity levels for each attribute, 
and as such, DCE methods may be applied to generate utility value 
sets. DCEs incorporating an attribute for duration (time trade- off; 
DCETTO) can be used to compare value sets by different respondent 
groups.
It has been suggested that patients with haemophilia rate their 
health states higher than the general population in some scenarios, 
but this has not been thoroughly explored or quantified.13,14 We con-
ducted a DCETTO using the EQ- 5D- 5L to investigate the potential of 
a disability paradox among patients with haemophilia. Using discrete 
choice methods allowed us to assess self- reported preferences for 
incremental health state scenarios that can be compared between 
patients and otherwise healthy peers to characterize differences at-
tributable to disease.12 We also quantified differences in reported 
health state valuations between patients with haemophilia and a 
representative sample of the US general population. Our aim was to 
identify and characterize the need for adjustments in the evaluation 
of patient- reported burden of haemophilia and effects of treatment 
on functionality and QoL.
2  |  Methods
2.1  |  Study design
In this study, a DCETTO was designed to present individuals with 
hypothetical health states (known as ‘choice sets’) and ask them to 
choose among a number of alternatives (or ‘attributes’). The choice 
sets presented each of the five dimensions of the preference- based 
measure EQ- 5D- 5L and one duration attribute, as described in 
Table 1. Each dimension (mobility, self- care, usual activities, pain/
discomfort and anxiety/depression) had five ordinal levels of sever-
ity (none, slight, moderate, severe, extreme/unable). The duration 
attribute contained five levels (3, 5, 7, 10 and 12 years) to investi-
gate preferences with respect to both their dimensions and potential 
durations.15
Health description A Health description B
Mobility I have no problems in walking 
about
I have slight problems in 
walking about
Self- Care I have no problems washing or 
dressing myself
I have no problems washing 
or dressing myself
Usual Activities I have severe problems doing 
my usual activities
I have no problems doing 
my usual activities
Pain/Discomfort I have slight pain or discomfort I have no pain or discomfort
Anxiety/Depression I am extremely anxious or 
depressed
I am not anxious or 
depressed
Duration You live in this health state for 
5 years and then you die
You live in this health state 
for 10 years and then 
you die
Which scenario do you 
think is better?
☐ ☒
TA B L E  1  Example of a hypothetical 
choice task used in the DCE design
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The sum of all possible dimension and duration levels yielded 
a total of more than 240 million potential choice sets; therefore, 
a subset of choice sets was generated by maximizing D- efficiency 
using Ngene software.16 D- efficiency is used to achieve optimal ef-
ficiency in DCEs by maximizing the information gained from a sub-
set of choice sets while minimizing error.17 The design included 120 
choice sets based on D- efficient design using the modified Fedorov 
algorithm.18
Each respondent completed 15 choice sets for the survey. This 
included 13 choice sets randomly selected for each respondent from 
the DCE design of 120 choice sets. Two more choice sets were in-
cluded as quality check measures. A repeated choice set was pre-
sented with one of the 13 choice sets being repeated in the exercise. 
A dominated choice set was where one of the scenarios had unam-
biguously worse levels for each attribute of the EQ- 5D- 5L than the 
other scenario.19
2.2  |  Study population, setting & study size
Between July and September 2019, adult patients with haemo-
philia (PwH), caregivers of PwH and a representative sample of the 
English- speaking US general population (GP) in terms of age, gender 
and region were recruited via a market research panel. We recruited 
250 PwH and 2000 general population respondents.20 The target 
sample size represented a trade- off between the desire for accu-
rate estimates (one that reflects the average preferences for PwH) 
and the practical consideration that haemophilia is a rare disease. 
The survey was conducted via a secure online portal. We first con-
ducted a pilot study to evaluate participant comprehension of the 
choice set tasks and the survey functionality. The pilot study in-
cluded a 10% subset of 200 GP, 25 PwH and 25 caregivers. We also 
assessed the duration attribute in the DCETTO design to compare 
shorter (3, 5, 7, 10 and 12 years) and longer durations (10, 12, 15, 17 
and 20 years) using the reliability tests of repeated and dominated 
scenarios. Shorter duration performed better and was selected for 
the research.
Upon entering the portal, participants were introduced to the 
study and had to provide informed consent in order to continue. 
Baseline demographic data were then collected before the partic-
ipants were presented with the DCETTO tasks. Informed consent 
was obtained from all participants, and the study was conducted in 
accordance with Declaration of Helsinki. Institutional Review Board 
(IRB) exemption was determined by the New England IRB.
2.3  |  Analysis
The primary analyses compared responses from PwH and the GP. 
We also collected responses from caregivers of PwH; however, many 
caregivers had haemophilia themselves and thus were not included 
in the analyses to avoid confounding. To reduce uncertainty around 
the heterogeneity between cohorts, only male PwH were included 
and the age distribution was matched between the GP and PwH. 
Age matching was achieved by random sampling of the GP to match 
the PwH proportions by age group and was repeated five times to 
increase the robustness of resampling for multiple subgroups. The 
results from the resampling were then aggregated to generate mean 
values from random sampling responses.
Data were then modelled using conditional- logit regressions 
to produce an adjusted value set for PwH and the GP.12 The util-
ity value sets were examined for inconsistencies and ordering was 
imposed for transitivity. Therefore, any preceding attributes were 
equal than or less than the current attribute, for example if level 2 
of an attribute was greater than the utility of level 1, the two levels 
would be merged. This method has been commonly used to ensure 
the applicability of the DCE results.21 Models for PwH and the GP 
were compared to test whether the models were on the same scale 
using a likelihood ratio statistic (LR). An LR test posed the null hy-
pothesis that the PwH and GP models had preference homogeneity. 
If the LR statistic was above a critical value (calculated as the dif-
ference between the number of parameters in both models), then 
the null hypothesis was rejected, and the difference was considered 
statistically significant.
From the adjusted value sets generated for PwH and GP, we es-
timated values for every possible EQ- 5D- 5L state. Two utilities for 
each population (PwH and GP) were compared for the average util-
ity difference across health states and the frequency of the average 
utility were valued higher or lower. Analyses were also conducted 
for subgroups including by haemophilia type (A and B) and severity 
(severe and moderate; the sample size for patients with mild hae-
mophilia was too small for robust analyses). All analyses were per-
formed using Stata 16 (StataCorp).
3  |  RESULTS
3.1  |  Sample
Of the 2183 participants that completed the DCE, 856 (39.2%; 106 
[4.9%] PwH and 750 [34.4%] GP) respondents indicated inconsisten-
cies based on the reliability tests and were excluded from the analy-
ses. A total of 1327 participants remained (1150 GP and 177 PwH, 
including 118 PwHA and 59 PwHB). Demographic characteristics 
were generally similar between PwH and the GP except that more 
patients from the GP than PwH were ≥55 years of age (31% vs 11%; 
p < .001), and more PwH were men (77% vs 49%; p < .001; Table 2); 
therefore, sex and age matching were applied for the analyses.
3.2  |  Comparison of PwH and the GP
PwH were found to provide higher values for 98.9% of EQ- 5D- 5L 
states compared to the GP (Table 3). Figure 1 presents the relative 
utility values, which illustrates that PwH value states were consist-
ently higher than GP value states with a utility value of 0.9 or less. 
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The mean HSV difference between PwH and the GP was 0.17 across 
all possible EQ- 5D- 5L states. An approximation of the minimal clini-
cally important difference (MCID) for the EQ- 5D- 5L based on EQ- 
5D- 3L values was used as EQ- 5D- 5L US MCIDs are not available; 
therefore, the MCID is reported as 0.0722 indicating that the HSV 
difference between PwH and the GP was clinically meaningful. LR 
tests also showed that the two utility scales differed significantly 
between responses from PwH and the GP (LR = 36.34; p < .01).
EQ- 5D- 5L individual attribute mean utility values are illus-
trated in Figure 2. The results indicated that mobility and self- care 
attributes were associated with a greater impact on QoL for PwH 
across all five levels of severity.
3.3  |  Subgroup analysis of haemophilia 
type and severity
For PwHA and PwHB, utility valuations were found to be higher 
for 96.5% and 97.4% of EQ- 5D- 5L states compared to valuations by 
the GP (Table 3), respectively. Figure S1 presents the relative utility 
TA B L E  2  Characteristics for participants included in the analysis
Characteristics
People with haemophilia General population
p- Value
(PwH vs GP)Type A (n = 94) Type B (n = 46) Total (n = 140) Total (n = 562)
Age (y), mean ± SD 36.7 ± 11.9 34.1 ± 10.5 35.9 ± 11.5 46.3 ± 15.6 <.001
Age groups (y), n (%)
18– 34 52.1 (52.1) 28 (60.9) 77 (55.0) 158 (28.1) <.001
35– 54 35 (37.2) 14 (30.4) 49 (35.0) 220 (39.2) .367
>55 10 (10.6) 4 (8.7) 14 (10.0) 184 (32.7) <.001
Race, n (%)
White 75 (79.8) 33 (71.7) 108 (77.1) 433 (77.1) .981
Black African American 9 (9.6) 6 (13.0) 15 (10.7) 59 (10.5) .941
American Indian/ Alaskan Native 1 (1.1) 0 (0) 1 (0.7) 6 (1.1) .707
Asian 4 (4.3) 3 (6.5) 7 (5.0) 28 (5.0) .993
Hawaiian/Pacific 1 (1.1) 0 (0) 1 (0.7) 3 (0.5) .800
Other 4 (4.3) 3 (6.5) 7 (5.0) 28 (5.0) .993
Not stated 0 (0) 0 (0) 1 (0.7) 5 (0.9) .840
Region, n (%)
Northeast 16 (17.0) 4 (8.7) 20 (14.3) 71 (12.6) .603
Midwest 26 (27.7) 11 (23.9) 37 (26.4) 113 (20.1) .103
South 34 (36.2) 21 (45.7) 55 (39.3) 189 (33.6) .209
West 18 (19.2) 10 (21.7) 28 (20.0) 189 (33.6) .002
Chronic comorbidities, n (%)
Any 94 (100) 46 (100) 140 (100) 287 (51.1) <.001
Haemophilia 94 (100) 46 (100) 140 (100) 0 (0) <.001
Tiredness/fatigue 7 (7.5) 9 (19.6) 16 (11.4) 49 (17.1) .127
Pain 21 (22.3) 9 (19.6) 30 (21.4) 92 (32.1) .022
Insomnia 4 (4.3) 8 (17.4) 12 (8.6) 36 (12.5) .223
Anxiety/nerves 14 (14.9) 10 (21.7) 24 (17.1) 63 (22.0) .247
Depression 16 (17.0) 10 (21.7) 26 (18.6) 82 (28.6) .026
Diabetes 6 (6.4) 0 (0) 6 (4.3) 59 (20.6) <.001
Breathing problems 6 (6.4) 4 (8.7) 10 (7.1) 52 (18.1) .003
Heart disease 0 (0) 0 (0) 0 (0) 32 (11.2) <.001
High blood pressure 16 (17.0) 3 (6.5) 19 (13.6) 111 (38.7) <.001
Osteoarthritis 14 (14.9) 3 (6.5) 17 (12.1) 26 (9.1) .320
Stroke 1 (1.1) 1 (2.2) 2 (1.4) 5 (1.7) .811
Cancer 1 (1.1) 0 (0) 1 (0.7) 11 (3.8) .067
Other 4 (4.3) 7 (15.2) 11 (7.9) 108 (37.6) <.001
Abbreviations: GP, General Population; N, number; PwH, People with Haemophilia; SD, standard deviation; Y, year.
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values of PwHA and PwHB compared to GP. The mean HSV differ-
ence was 0.17 (PwHA) and 0.21 (PwHB) relative to the GP, both ex-
ceeding the MCID of the EQ- 5D- 5L. LR tests also showed that the 
utility scales differed significantly between responses from PwHA 
and the GP (LR = 33.08; p < .001) and PwHB and GP (LR = 30.44; 
p < .01).
For people with severe haemophilia (PwSH) and people with 
moderate haemophilia (PwMH), utility valuations were found to be 
higher for 95.4% and 98.9% of EQ- 5D- 5L states compared to valu-
ations by the GP (Table 3), respectively. Figure S2 presents the rel-
ative utility values of PwSH and PwMH compared to the GP. The 
mean HSV difference was 0.14 (PwSH) and 0.17 (PwMH) relative 
to the GP, both exceeding the MCID of the EQ- 5D- 5L. LR tests also 
showed that the utility scales differed significantly between re-
sponses from PwSH and the GP (LR = 31.32; p < .01); however, this 
was not seen for PwMH and GP (LR = 11.77; p = .4645).
TA B L E  3  Comparative EQ- 5D- 5L value sets by haemophilia type and severity.
PwH vs GP PwHA vs GP PwHB vs GP PwSH vs GP
PwMH vs 
GP
Comparison of the utility scores:
PWH > GP, n (%) 3091 (98.91) 3017 (96.54) 3043 (97.38) 2982 (95.42) 3089 (98.85)
GP > PWH, n (%) 33 (1.06) 107 (3.42) 81 (2.59) 142 (4.54) 35 (1.12)
No difference, n (%) 1 (0.03) 1 (0.03) 1 (0.03) 1 (0.03) 1 (0.03)
Difference in utility score (PWH vs GP):
Mean (SD) 0.17 (0.08) 0.17 (0.10) 0.21 (0.11) 0.14 (0.09) 0.17 (0.08)
Median (IQR) 0.17 (0.11) 0.17 (0.10) 0.21 (0.17) 0.14 (0.13) 0.16 (0.11)
Abbreviations: EQ- 5D- 5L, EuroQol- 5- dimensions 5- level; GP, general population; IQR, interquartile range; N, number; PwHA, people with 
haemophilia A; PwHB, people with haemophilia B; PwMH, people with moderate haemophilia; PwSH, people with severe haemophilia; SD, standard 
deviation; Y, year.
F I G U R E  1  Graphical representation of observed utility of PwH compared to actual utility. Abbreviations: PwH, people with haemophilia. 
Note: Actual utility describes the utility that was observed by the general population. Observed utility describes the corresponding utility 
that was elicited from PwH. Based on utility decrements derived from the DCETTO for the EQ- 5D- 5L across 3125 states, corresponding 
health state utility values were derived. Using 0.05 utility intervals, based on health state utility values derived from the general population, 
corresponding values derived from PwH were plotted. For each 0.05 interval and utility value reported by the general population, the 
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4  |  DISCUSSION
Our study revealed evidence of the disability paradox in haemo-
philia patient- reported outcomes, where people with haemophilia 
reported significantly higher health state valuations than otherwise 
healthy peers from the general US population. This difference was 
both statistically significant and clinically meaningful, with con-
sistent results across haemophilia A and B as well as severe and 
moderate patients. These findings should be considered in the de-
sign and interpretation of patient- reported outcomes research in 
haemophilia.
Our findings are consistent with studies of disease state adap-
tation reported in haemophilia and other chronic conditions, where 
patients have reported higher health states than otherwise healthy 
peers.23- 25 A recent patient preference study by Carlsson et al. 
(2017)25 showed that patients with haemophilia A consistently rated 
their health states higher than their peers in the GP (score range, 
0.67– 0.73 for PwHA vs 0.54– 0.60 for the GP). Our study indicated 
a disability paradox in PwH using a validated, widely used QoL in-
strument, the EQ- 5D- 5L. Our application of the composite DCETTO 
method to include consideration of the duration of health states 
offers a robust approach not only to test for the existence of the 
disability paradox, but also to quantify its impact. Gandhi and col-
leagues (2017)23 observed that patients with heart disease or cancer 
reported similar health state utility values as the general population 
when adjusted for sociodemographic characteristics. Peeters and 
Stiggelbout (2010)24 conducted a meta- analysis showing that pa-
tients across a variety of conditions generally provided higher health 
state valuations than ‘non- patients’ from the GP. Alternatively, sim-
ilar health state valuations have been reported between patients 
with epilepsy and healthy peers, and worse ratings for those with 
dementia compared to the GP.26,27 In the context of this broader 
heterogeneity, our findings support the use of haemophilia- specific 
health utility assessments for the accurate design and interpretation 
of patient- centric research.
Our work has implications for clinical research assessments 
and for broader population health management and policy de-
cisions. In the pursuit of greater health equity for people with 
haemophilia, patient- centric outcome measures are used more 
often and with greater consideration. We observed and quanti-
fied a disability paradox in PwH- rated health states using the EQ- 
5D- 5L. The frequent use of this instrument in clinical research 
and health technology assessments emphasizes the likelihood 
that disease burden is underestimated and treatment effect is 
under- valued when the disease state adaptation is not factored 
into totality of treatment benefits and health technology evalu-
ations. As novel treatment options such as gene therapy emerge 
with the potential to approach a functional cure,28,29 the charac-
terization of patient- centric value should account for the ‘true’ 
burden of haemophilia and relative improvements offered by new 
therapeutic strategies.
This study should also be considered in the context of certain 
strengths and limitations. We utilized the validated EQ- 5D- 5L for 
patient- reported outcomes, which should offer some generalizabil-
ity to future research efforts using the same instrument. The DCE 
and time trade- off methods are common in health services research. 
Since the DCETTO was completed online, without an in- person fa-
cilitator to guide the respondent through the activity, there may 
have been some impact on the accuracy of responses if a participant 
did not fully understand a given question30; however, we sought to 
account for this potential limitation by removing inconsistent re-
sponses in the analysis. Due to haemophilia being a rare condition, 
we were limited by sample size in our subgroup analysis; future re-
search could address these subgroups with a larger sample size to 
see if the findings hold true. Unobserved patient characteristics and 
contextual factors may have contributed to the heterogeneity of 
reported preferences. Further research may account for additional 
observable characteristics that may differ between cohorts, such 
as the presence of comorbidities or additional sociodemographic 
considerations.
F I G U R E  2  Graphical representation of 
the EQ- 5D- 5L coefficients for PwH and 
GP. Abbreviations: MO, Mobility; SC, Self- 
Care; UA, Usual Activities; PD, Pain and 
Discomfort; AD, Anxiety and Depression; 
PwH; people with haemophilia. Notes: 
By domain, the levels of responses range 
from no problems to severe problems 
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5  |  CONCLUSION
Our findings indicated the presence of a disability paradox in the 
population preferences for haemophilia. Clinical and health tech-
nology assessments should account for health state- derived QoL 
evaluations specific to people with haemophilia. The unmet needs 
identified in current standards of care are likely to underestimate 
the burden of haemophilia on patients and caregivers, and stand-
ard QoL instruments that do not account for the disability para-
dox may not be accurate for clinical assessments and health policy 
decisions.
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